Ugo Pastorino
National Institutes of Health
CancerPathologyLung cancerLungMedicine
What is this?
Publications 392
#1Federico Rea (University of Milano-Bicocca)H-Index: 34
#2Francesca Ieva (Polytechnic University of Milan)H-Index: 12
Last. Giovanni Corrao (University of Milano-Bicocca)H-Index: 46
view all 8 authors...
#1William D. Travis (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 116
#2Sanja Dacic (University of Pittsburgh)H-Index: 45
Last. Gang Chen (Fudan University)H-Index: 8
view all 43 authors...
Abstract Currently there is no established guidance on how to process and evaluate resected lung cancer specimens following neoadjuvant therapy in the setting of clinical trials and clinical practice. There is also a lack of precise definitions on the degree of pathologic response, including major pathologic response (MPR) or complete pathologic response (CPR). In other cancers such as osteosarcoma, colorectal, breast and esophageal carcinomas, there have been multiple studies investigating path...
#1Cristina BorziH-Index: 5
#2Linda CalzolariH-Index: 1
Last. Orazio FortunatoH-Index: 6
view all 7 authors...
Lung cancer causes approximately one fifth of all cancer deaths. Tumour cells actively communicate with the surrounding microenvironment to support malignant progression. Extracellular vesicles (EVs) play a pivotal role in intercellular communication and modulate recipient cells by delivering their contents, including proteins and nucleic acids such as microRNAs (miRNAs). We isolated EVs from the conditioned medium (CM) of human lung cancer cell lines and plasma of lung cancer patients and cance...
1 CitationsSource
#1Francesca BianchiH-Index: 14
#2Massimo MilioneH-Index: 25
Last. Lucia Sfondrini (University of Milan)H-Index: 15
view all 13 authors...
Immune and epithelial cells express TLR3, a receptor deputed to respond to microbial signals activating the immune response. The prognostic value of TLR3 in cancer is debated and no data are currently available in NSCLC, for which therapeutic approaches that target the immune system are providing encouraging results. Dissecting the lung immune microenvironment could provide new prognostic markers, especially for early stage NSCLC for which surgery is the only treatment option. In this study we i...
1 CitationsSource
#1John K. Field (University of Liverpool)H-Index: 65
Last. Helmut Prosch (Medical University of Vienna)H-Index: 14
view all 8 authors...
Recent randomised trials on screening with low-dose CT have shown important reductions in lung cancer (LC) mortality and have triggered international efforts to implement LC screening. Detection rates of stage I LC with volume CT approaching 70% have been demonstrated. In April 2019 ‘ESMO Open – Cancer Horizons’ convened a roundtable discussion on the challenges and potential solutions regarding the implementation of LC screening in Europe. The expert panel reviewed the current evidence for LC s...
#1Gianluca Milanese (University of Parma)H-Index: 3
#2Mario Silva (University of Parma)H-Index: 10
Last. Ugo PastorinoH-Index: 56
view all 10 authors...
PURPOSE To test ultra-low-dose computed tomography (ULDCT) scanning protocols for the detection of pulmonary nodules (PN). METHODS A chest phantom containing 19 solid and 11 subsolid PNs was scanned on a third-generation dual-source computed tomography (CT) scanner. Five ULDCT scans (Sn100kVp and 120, 70, 50, 30, and 20 reference mAs, using tube current modulation), reconstructed with iterative reconstruction (IR) algorithm at strength levels 2, 3, 4, and 5, were compared with standard CT (120kV...
1 CitationsSource
#1Gabriella SozziH-Index: 56
#2Mattia BoeriH-Index: 13
Last. Ugo PastorinoH-Index: 56
view all 3 authors...
#1Ugo PastorinoH-Index: 56
#2Mattia BoeriH-Index: 13
Last. Gabriella SozziH-Index: 56
view all 12 authors...
2 CitationsSource